Spectrum Cannabis joins Cannabis Standard – the cannabis formulary for employers, consumers and Doctors

Spectrum Cannabis joins Cannabis Standard – the evidence-based medical cannabis formulary for Customers, employers and Doctors

Reformulary Group, a Canadian health care, science and technology firm, today announced it has signed Spectrum Cannabis, a wholly-owned subsidiary of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth”) as a medical cannabis partner for its Cannabis Standard™ formulary.

The inclusion of Spectrum Cannabis — a company dedicated to simplifying medical cannabis for patients and health care practitioners — will provide Canadians and employers that subscribe to Cannabis Standard with a number of Spectrum Cannabis goods (such as whole flower cannabis, oils and Softgels) and preferred pricing options.  

Cannabis Standard features a technology platform to catch individual results, to mobilize patients in helping to create’study’ that illustrates the benefits of cannabis for a variety of conditions. Patients will self-report in an intuitive platform that employs a survey tool to document improvements in their health using metrics that are applicable. There is a support system, which together with patients generating their own evidence is anticipated to have a significant social impact.  

“Spectrum Cannabis is a trailblazer in medical cannabis and a significant addition to Cannabis Standard,” explained Helen Stevenson, Reformulary Group founder and CEO. “The company is a leading producer of high-quality medical cannabis products and strengthens our network of LP partnerships and cannabis products.”

Cannabis Standard provides guidelines to help determine if cannabis is the treatment that is right, based on a comprehensive review of the best available evidence as well as expert advice. These guidelines include specific strains based on medical conditions, evidence, and symptoms. The guidelines were developed by Reformulary Group’s medical cannabis expert committee, which comprises several renowned clinicians.

“By partnering with Reformulary Group through their innovative Cannabis Standard program, we’re helping Canadians and their companies navigate the intricacies of medical cannabis whilst also contributing to an important data-collecting tool that can demonstrate the utility of cannabis treating various medical problems.”

Around Reformulary Group
Founded in 2011, Reformulary Group is an expert-led health care technology firm focused on ensuring drug plan sustainability, and helping employers and Canadians make medication and medical cannabis options. The corporation’s proprietary list, the Reformulary®, is a subscription-based service offered to Canadian companies. The Reformulary provides doctors and nurse practitioners with invaluable drug information, reviewed and vetted by an independent committee of doctors and pharmacists from across Canada. The business’s award-winning DrugFinder™ provides information to enable patients to make medication choices. A platform that gives guidelines for cannabis use based on evidence and expert advice, Cannabis Standard was developed by reformulary Group. Cannabis options that are smart are enabled by cannabis Standard by Canadians. For more information see www.reformulary.com.

About Spectrum Cannabis
Spectrum Cannabis, a wholly-owned subsidiary of Canopy Growth, is dedicated to simplifying medical cannabis for health care practitioners and patients. Spectrum Cannabis is an international medical business which interfaces around the globe with health care professionals and patients. Founded in Canada, Spectrum Cannabis operates in Africa, South America, Australia and across Europe. Spectrum Cannabis products can be found in a wide range of formats and potencies designed to simplify the dialogue around dosage and strength by applying a Spectrum that is colour-coded to categorize medical cannabis according to CBD and THC levels. Its product lineup includes whole flower cannabis, oils and innovations such as Softgels. Through easy dosing formats product simplification, and continuing education of health care professionals, Spectrum Cannabis is committed to improving the lives of medical cannabis patients .

About Canopy Growth Corporation
Canopy Growth is a cannabis and hemp firm, offering distinct brands and cannabis varieties that are curated in Softgel, oil and dried capsule types. From process and product innovation to market implementation, Canopy Growth is driven by a passion for leadership and a commitment to creating a world-class cannabis company one product, site and country at a time. The business has operations in 12 countries across five continents. The business is proudly dedicated to educating healthcare practitioners, conducting robust clinical study, and furthering the public’s understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations, has committed millions of dollars toward cutting edge, commercializable research and IP development. Through subsidiary Canopy Rivers Corporation, the Company is providing new market entrants with resources and investment and building a portfolio of investments in the sector. From our historical listing on the Toronto Stock Exchange and New York Stock Exchange to our global growth, in advancing shareholder value pride is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with sector names including cannabis icon Snoop Dogg, breeding DNA Genetics and Green House seeds, and Fortune 500 alcohol pioneer Constellation Brands to legends, to name but a few. Canopy Growth operates ten licensed cannabis production websites with over 4.3 million square feet of manufacturing capacity, including over 500,000 square feet of GMP certified manufacturing space. For more information see www.canopygrowth.com.

This news release contains”forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and”forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of these statements include”will provide Canadians and companies that subscribe to Cannabis Standard using a range of Spectrum Cannabis goods”, and”is expected to have a significant social impact.” Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by these forward-looking information, including: product supply, self-reporting by individuals, and these risks within the firm’s annual information form dated June 28, 2018 and filed with Canadian securities regulators which can be found on the Company’s issuer profile on SEDAR in www.sedar.com. Even though the Company believes that the assumptions and factors used in preparing the forward-looking info or forward-looking statements in this news release are reasonable, undue reliance shouldn’t be put on such information and no assurance can be given that such events will occur in the revealed time frames or at all. The forward-looking info and forward-looking statements contained in this news release are made as of the date of this news release and the Company doesn’t undertake an obligation to publicly update such forward-looking info or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

SOURCE Canopy Growth Corporation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2018/20/c2996.html

Released at Tue, 20 Nov 2018 12:34:38 +0000

Posted in: News

Comments are closed.